TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03683667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Oral Product
Description: Azithromycin oral suspension (10 mg/kg; 3 days) administered by study personnel at 6 and 9 months of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Oral Product
Description: Azithromycin oral suspension (10 mg/kg; 3 days) administered by study personnel at 6 and 9 months of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Oral Product
Description: Azithromycin oral suspension (10 mg/kg; 3 days) administered by study personnel at 6 and 9 months of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Oral Product
Description: Azithromycin oral suspension (10 mg/kg; 3 days) administered by study personnel at 6 and 9 months of age

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Contain inert excipients only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Contain inert excipients only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Contain inert excipients only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Contain inert excipients only

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplement
Description: Blended food providing 125 kcal and 10 g protein as egg white powder prepared as porridge and fed daily to infants from 6-12 months of age
Study: NCT03708419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboptimal diet
Description: The optimal diet for the other metabolic phenotype will be considered as suboptimal/ control diet. For the MIR phenotype this is the high protein, high fiber, low fat diet; for the LIR phenotype this is the high monounsaturated fatty acid diet. See the description above.
Study: NCT04262141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-7289
Description: Daily oral dose of 0.6 mg/kg/day IMG-7829 capsules. Dose escalation an de-escalation rules applied as necessary.
Study: NCT02338518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: oxaliplatin 100 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group and SOX group.~Intravenous oxaliplatin 130 mg/m2 was administered on day 1 of every cycle in SOX group.
Study: NCT00432133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protection Motivation Theory-Based Intervention
Description: Targets perceptions of outcome severity and susceptibility, self-efficacy, response efficacy, response costs, and rewards of physical inactivity. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
Study: NCT03683667

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Supplement
Description: Blended food providing 125 kcal and 10 g protein as egg white powder prepared as porridge and fed daily to infants from 6-12 months of age

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isocaloric Supplement
Description: Blended food providing 125 kcal and 1 g protein as rice powder prepared as porridge and fed daily to infants from 6-12 months of age

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric Supplement
Description: Blended food providing 125 kcal and 1 g protein as rice powder prepared as porridge and fed daily to infants from 6-12 months of age

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg
Description: Egg provided daily to infants from 6-12 months of age

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg
Description: Egg provided daily to infants from 6-12 months of age

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Monthly messaging on infant and young child feeding

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Monthly messaging on infant and young child feeding

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Monthly messaging on infant and young child feeding
Study: NCT00432133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protection Motivation Theory-Based Intervention
Description: Targets perceptions of outcome severity and susceptibility, self-efficacy, response efficacy, response costs, and rewards of physical inactivity. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmenta
Description: Targets increased awareness and use of local parks and trials near the home and work environments. Targets increased access by providing membership to a local fitness facility for 12 months. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
Study: NCT03683667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Monthly messaging on infant and young child feeding

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition Education
Description: Monthly messaging on infant and young child feeding

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Monthly messaging on infant and young child feeding
Study: NCT04331197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole 2.5mg
Description: Femara 2.5 mg, 2 tablets orally every day from day 2-5 of the period for 5 days
Study: NCT00056056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bexarotene
Description: The recommended initial dosage of Bexarotene (75 mg Bexarotene capsules to be administered according to body surface area) for patients entered in this trial is 300 mg/m2 /once a day, taken orally, till CCR, PD, unacceptable toxicity, 16 weeks of treatment, whichever comes first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxypsoralen
Description: The dose of methoxypsoralen, as conventional capsules or liquid-filled capsules, is based on the patient's weight. The standard dose of 0.6 mg/kg will be given to all patients three times weekly - Increasing dose of PUVA according to a set protocol after a Minimal Phototoxic Dose (MPD) testing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methoxypsoralen
Description: The dose of methoxypsoralen, as conventional capsules or liquid-filled capsules, is based on the patient's weight. The standard dose of 0.6 mg/kg will be given to all patients three times weekly - Increasing dose of PUVA according to a set protocol after a Minimal Phototoxic Dose (MPD) testing.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UV light therapy
Description: Initial UVA light exposure times should be based on the minimal phototoxic dose (MPD) for the specific light source being used. MPD can be determined by irradiating several skin areas 2 cm in diameter with varying light exposure times and determining the exposure time that produces erythema at 72 hours. The initial dose of UVA administered will be 70% of the MPD. The dose of UVA for the subsequent UVA sessions will be increased according to a standard protocol consisting of 20% increments with each successive treatment session depending on the presence of erythema.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UV light therapy
Description: Initial UVA light exposure times should be based on the minimal phototoxic dose (MPD) for the specific light source being used. MPD can be determined by irradiating several skin areas 2 cm in diameter with varying light exposure times and determining the exposure time that produces erythema at 72 hours. The initial dose of UVA administered will be 70% of the MPD. The dose of UVA for the subsequent UVA sessions will be increased according to a standard protocol consisting of 20% increments with each successive treatment session depending on the presence of erythema.
Study: NCT03101267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4070
Description: Intradermal vaccination at 2-week intervals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4070
Description: Intradermal vaccination at 2-week intervals

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal vaccination at 2-week intervals
Study: NCT03195296

Intervention type: OTHER
Intervention: No intervention
Description: No intervention related to the study is foreseen
Study: NCT03464565

Intervention type: DEVICE
Intervention: Penumbra System
Description: Penumbra System
Study: NCT02338518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: oxaliplatin 100 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group and SOX group.~Intravenous oxaliplatin 130 mg/m2 was administered on day 1 of every cycle in SOX group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: etoposide 80 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
Study: NCT02218177

Intervention type: DRUG
Intervention: Aflibercept
Description: anti-VEGF treatment for wet age related macular degeneration

Intervention type: DRUG
Intervention: Ranibizumab
Description: anti-VEGF treatment for wet age related macular degeneration

Intervention type: PROCEDURE
Intervention: Combination Photodynamic Therapy
Description: Use of cold laser with an intravitreal injection of dexamethasone to treat wet age related macular degeneration
Study: NCT00432133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmenta
Description: Targets increased awareness and use of local parks and trials near the home and work environments. Targets increased access by providing membership to a local fitness facility for 12 months. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
Study: NCT00649961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin injection
Description: A single intravenous infusion of melatonin will be given to each infant over 6 hours so that successive groups will receive increasing doses until the correct dose for age is found.~Based on the pharmacokinetics and clearance of melatonin in adults an approximate dose has been calculated. The starting dose of melatonin will be 0.1 microgram/kg/hr to be given over 6 hours intravenously. The range of expected dose is 0.1-0.5 microgram/kg/hr.
Study: NCT00936091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin A supplements
Description: gelatinous and reddish opaque capsules containing 200 000 IU vitamin A
Study: NCT03180762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284 0.1 mg
Description: 0.1 mg of JNJ-64140284 will be administered as an oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284 0.5 mg
Description: 0.5 mg of JNJ-64140284 will be administered as an oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284 2.5 mg
Description: 2.5 mg of JNJ-64140284 will be administered as an oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284 10 mg
Description: 10 mg of JNJ-64140284 will be administered as an oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284 50 mg
Description: 50 mg of JNJ-64140284 will be administered as an oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284 150 mg
Description: 150 mg of JNJ-64140284 will be administered as an oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284 (dose to be determined [TBD])
Description: JNJ-64140284 (dose to be determined) will be administered as an oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284 (dose to be determined [TBD])
Description: JNJ-64140284 (dose to be determined) will be administered as an oral solution.
Study: NCT00936091

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 125 children received placebo capsules
Study: NCT04168632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPTIMAT
Description: The intervention was to serve a new school lunch menu plan as similar as possible to a baseline menu plan but 40% lower in greenhouse gas emissions, being nutritionally adequate and no more expensive.
Study: NCT00801671

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cPAP
Description: After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: cPAP
Description: After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)
Study: NCT00941577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIR645
Description: AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiologic saline solution
Description: Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
Study: NCT05158647

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 10-ml 0.5% isobaric bupivacaine and 1ml normal saline were prepared for IIIH blockade

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MgSo4
Description: 10 ml 0.5% isobaric bupivacaine and 1ml of MgSo4 10% (100 mg) were used
Study: NCT03139942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical spectral reflectance and autofluorescence imaging
Description: When a suitable area of tissue is identified by the clinician during a patient's colonoscopy (e.g., a polyp), the imaging probe is inserted into the colonoscope so that it can view the tissue. Optical spectral reflectance and autofluorescence imaging is then performed to collect white light reflected by, and fluorescent light emitted from, the tissue. This is then analysed by hardware and software components in the external analysis unit.
Study: NCT01456377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: predinose oral
Description: 1 mg for kg for 3 wekees

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: use a oral placebo
Study: NCT00712062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
Study: NCT02036554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
Study: NCT03683667

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition Education
Description: Monthly messaging on infant and young child feeding

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education
Description: Monthly messaging on infant and young child feeding
Study: NCT03684928

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A (test)
Description: Daily wear contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A (test)
Description: Daily wear contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon C (control)
Description: Daily wear contact lenses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon C (control)
Description: Daily wear contact lenses
Study: NCT02821676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PECI/SPB Block with Active Anesthetic + Placebo Multilevel Intercostal Nerve Block followed by Latissimus Dorsi Flap Breast Reconstruction
Description: 30mL of 0.5% Ropivacaine with 1:200,000 epinephrine preoperatively via an ultrasound guided PECI/SPB regional block and 5mL of Normal Saline intraoperatively as an intercostal nerve block to each of the T2-T7 nerve segments
Study: NCT02338518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pharmorubicin
Description: pharmorubicin 30 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 80\~120 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks in both SEEOX and SOX groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: 80\~120 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks in both SEEOX and SOX groups.
Study: NCT01423864

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: conventional ECMO with intravenous steroid
Description: refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome treated with intravenous steroid, Solu-Cortef 50mg q6h taper down when hemodynamic stable
Study: NCT03180762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered.
Study: NCT02948075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quisinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT02382263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4
Description: Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 days 1 \& 15 in a 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
Description: Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
Study: NCT02036554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
Study: NCT02382263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4
Description: Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1 \& 15 in a 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4
Description: Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1,8 \& 15 in a 28 days cycle
Study: NCT03816826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: both are physical therapy intervention technique used to treat the soft tissue acute injuries

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: both are physical therapy intervention technique used to treat the soft tissue acute injuries

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: both are physical therapy intervention technique used to treat the soft tissue acute injuries
Study: NCT04674904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling on Upper trapezius, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids for 10 min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hot pack , TENS , Stretching
Description: Treatments are~1. Hot Pack for 15 minutes~2. TENS for 10 minutes~3. Stretching~The third treatment which is Stretching will be given one time on each muscle (tight upper trap, Levator Scapulae, Sternocledomastoid , Pectorals major and minor and rhomboids) of upper spine
Study: NCT00553475

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Dosage: 300 mg/day (150 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Dosage: 600 mg/day (300 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
Study: NCT02916433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Study: NCT02036554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic acid
Description: Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
Study: NCT04059367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC9204-1177
Description: Increasing doses of NNC9204-1177 administered s.c. (subcutaneously, under the skin) in the stomach area once-weekly for 11 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocktail of 5 already approved drugs
Description: 5 medicines as tablets, capsules or syrup to be taken with water on Day 1 and Day 78 of the study
Study: NCT01652300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: two educational sessions
Description: The test group had two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: no education
Description: women in the control group received no education
Study: NCT03754231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart rate monitoring
Description: The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory rate monitoring
Description: The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing
Study: NCT00752596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azimilide 2HCl
Description: One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated
Study: NCT02678598

Intervention type: DRUG
Intervention: Micafungin
Description: Intravenous